News and Comments

IONIS Stock Selloff: Has GSK Abandoned the Wagon or Jumped Out of the Train? See Also: Osteoporosis

  Friday, May 27, 2016

 More...

Great News for Innoviva and COPD Patients

  Wednesday, May 25, 2016

GlaxoSmithKline and Innoviva: The COPD inhaler Relvar® Ellipta® (known as Brio Ellipta in the United States) Demonsterates Superiority Over Usual Care. More...

Exelixis: Results Demonstrate the Potential of Cabozantinib to Become the Gold Standard First Line Treatment for Advanced RCC

  Monday, May 23, 2016

Yes, indeed, the good news has come from the randomized CABOSUN phase 2 trial with Exelixis’ (EXEL) drug cabozantinib. The news is indirectly telling us that Cabozantinib may soon become the first-line treatment for previously untreated advanced renal cell carcinoma (RCC).  More...

Biogen: A Fruitful Collaboration in Gene Therapy. A Small Gene Therapy Firm That You Should Know

  Tuesday, May 17, 2016

COLLABORATIONS  More...

Seres Therapeutics Collaborates with Memorial Sloan Kettering Cancer Center to Improve Immunotherapy

  Friday, May 13, 2016

Seres Therapeutics (MCRB), is microbiome therapeutics platform company. It focuses on developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced.  More...

Exelixis Again. The Road to Defeating DMD. Two New Important IPOs

  Monday, May 09, 2016

EXELIXIS AGAIN More...

A Judge is Offended About False Claims Against Gilead. Good News from Regeneron

  Monday, May 02, 2016

GILEAD SCIENCES More...

The FDA Approval of Exelixis Drug Cabometyx™ Is Indeed Great News

  Tuesday, April 26, 2016

Congratulation.   More...

Nectar Therapeutics and Seattle Genetics at the AACR Meeting

  Tuesday, April 19, 2016

Meaningful Presentations  More...

Good News from Juno Therapeutics and from Abbvie. Disappointing News for Clovis Oncology

  Wednesday, April 13, 2016

Juno Therapeutics (JUNO) is due to receive a fee payment of $50 million from Celgene. The reason for this compensation is that Celgene has exercised its option to develop and commercialize Juno CD19 program outside North America and China.  More...


Recent Postings


Archive


Tags

PTC Therapeutics (PTCT) OSI (OSIP) Array Pharmaceuticals (ARRY) Idenix (IDIX) Agenus (AGEN) HALOZYME (HALO) Velcade (bortezomib) Sequenom (SQNM) ZALTRAP™ Tysabri BIOMARIN (BMRN) Regeneron (REGN) TOKAI (TKAOI) KERYX (KERX) Biocryst (BCRX) ARCA (ABIO) Alder Biopharmaceuticals (ALDR) Endometrial Cancer Sangamo (SGMO) Roche (ROCHE) Intercept (ICPT) GUARDIAN HEALTH Roche (RHHBY) ImmunoGen (IMGN) Gilead (GILD) Dendreon (DNDN) Human Genome Sciences (HGSI) Vitae Pharmaceuticals (VTAE) galapagos (GLPG) Genentech REGULUS (RGLS) Ridaforolimus KITE (KITE) Biogen Idec (BIIB) Exelixis (EXEL) Sanofi-Aventis (SAN) NANTKWEST (NK) Prolor Biotech (PBTH) JUNO (JUNO) Ziofpharm (ZIOP) Micromet (MITI) Auspex (ASPX) Agenus (AGEN SUNESIS PHARMACEUTICALS (SNSS) Revlimid (lenolidamide) Sanofi (SNY) AERIE PHARMACEUTICALS Herceptin Aimmune Therapeutics (AIMT) Sarepta (SRPT) SERES THERAPEUTICS (MCRB) Ionis (IONS) Human Longevity (HLI) Vertex (VRTX) Editas (EDIT) Amgen (AMGN) C4 Therapeutics Elan (ELN) ACADIA (ACAD) Abbott Laboratories (ABT) Illumina (ILMN) Incyte (INCY) Merck (MRK) Jazz Pharmaceuticals (JAZZ) Prosensa (RNA) Xoma (XOMA) Rapamune Sanofi (SNA) Onyx (ONXX) Zerenex Alnylam (ALNY) Intrexon (XON) Inovio (INO) Galena (GALE) IDERA (IDRA) Benlysta (belimumab) CompuGen (CGEN) Theravance (THRX) RenenxBio (RGNX) ADVENTRIX (ANX) Ariad (ARIA) Intermune (ITMN) Dynavax (DVAX) Bristol-Myers Squibb (BMY) Anadys (ANDS) Trastuzumab-DM1 ISIS (ISIS) Mirati Therapeutics (MRTX) Cytokinetics (CYTK) Telaprevir NEKTAR (NKTR)) GlaxoSmithKline (GSK) SYNTA (SNTA) Pluristem (PSTI) Seattle Genetics (SGEN) VANDA (VNDA) Theravance Bio Pharma (TBPH) Multiple Myeloma Anacor (ANAC) ABBVIE (ABBV) Valeant Pharmaceuticals International (VRX)